Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

131 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-21

Study Completion Date

2017-10-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective of this study is to compare the antimicrobial properties of an investigational agent to an active control and a negative control when applied to specific body locations. Testing will be performed according to the procedures outlined in the Food and Drug Administration Tentative Final Monograph (TFM) for Effectiveness Testing of a Patient Preoperative Skin Preparation

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

NCT03229759

Preoperative Skin Preparation

COMPLETED PHASE2

Preoperative Skin Preparation Evaluation

NCT00636480

Topical Antisepsis

COMPLETED PHASE3

In Vivo Efficacy Study of Patient Preoperative Preps

NCT02203591

Bacterial Reduction Post-product Application

COMPLETED PHASE3

In Vivo Preoperative Skin Preparation Persistence Evaluation

NCT03155178

Bacterial Recovery of Skin Flora Post-product Application

COMPLETED PHASE2

Clinical Evaluation of Patient Preoperative Prep

NCT02831816

Surgical Skin Preparation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preoperative Skin Preparation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational Product #1 (IP1)

octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear

Group Type EXPERIMENTAL

OCT - clear

Intervention Type DRUG

Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear

Investigational Product #2 (IP2)

octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted

Group Type EXPERIMENTAL

OCT- tinted

Intervention Type DRUG

Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted

Active Control

ChloraPrep® - Hi-Lite Orange® applicator

Group Type ACTIVE_COMPARATOR

ChloraPrep

Intervention Type OTHER

Active Control: ChloraPrep® - Hi-Lite Orange® applicator

Negative Control

sterile 0.9% saline applied with single use applicator

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type OTHER

Negative Control: sterile 0.9% saline applied with single use applicator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OCT - clear

Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear

Intervention Type DRUG

OCT- tinted

Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted

Intervention Type DRUG

ChloraPrep

Active Control: ChloraPrep® - Hi-Lite Orange® applicator

Intervention Type OTHER

Saline

Negative Control: sterile 0.9% saline applied with single use applicator

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects may be of either sex, at least 18 years of age and of any race.
* Subjects must be in good general health.
* Subjects must read and sign an Informed Consent Form, Authorization to Use and Disclose Protected Health Information Form, and the List of Restricted Products prior to participating in the study.
* Female subjects must complete a urine pregnancy test and have negative results documented before proceeding to treatment with test materials.
* All subjects must meet Screening Day microbial baseline requirements established by the sponsor.

Exclusion Criteria

* Known allergies or sensitivities to sunscreens, deodorants, laundry detergents, fragrances, vinyl, latex (rubber), alcohols, soaps, metals, inks, dyes, tape adhesives, or to common antibacterial agents found in soaps, lotions, ointments, or particularly the active ingredients of the study product drug solutions.
* Exposure of test sites to strong detergents, solvents, or other irritants within the 14-day product-restriction period or during the test period.
* Exposure of test sites to antimicrobial agents, medicated soaps, medicated shampoos, or medicated lotions, use of biocide-treated pools or hot tubs, use of tanning beds, or sunbathing during the 14-day product-restriction period or during the test period.
* Wear fabric softener-, bug repellent-, or UV-treated clothing during the 14-day product-restriction period or during the test period.
* Use of systemic or topical antibiotic medications, steroid medications (other than for hormonal contraception or post-menopausal reasons), or any other product known to affect the normal microbial flora of the skin during the 14-day product-restriction period or during the test period.
* A medical diagnosis of a physical condition, such as a current or recent severe illness, mitral valve prolapse with a heart murmur, congenital heart disease, hepatitis B, hepatitis C, an organ transplant, ports, or an immunocompromised condition such as AIDS (or HIV positive), lupus, medicated diabetes (Type 1 or 2), ulcerative colitis, Crohn's disease, asthma requiring daily medication, fibromyalgia or multiple sclerosis (medicated).
* Any tattoos or scars within 2 inches of the test sites; skin blemishes or warts may be permissible with the specific approval of the Principal Investigator or consulting physician.
* Dermatoses, cuts, lesions, active skin rashes, scabs, breaks in the skin or other skin disorders within 6 inches, on, or around the test sites.
* A currently active skin disease or inflammatory skin condition (for example, contact dermatitis, psoriasis, eczema) anywhere on the body that, in the opinion of the Principal Investigator, would compromise subject safety or study integrity.
* Subjects who receive an irritation score of 1 (any redness, swelling, rash, or dryness present in any treatment area) for any individual skin condition prior to the Screening Day baseline or Treatment Day baseline sample collection.
* Participation in another clinical study in the past 30 days or current participation in another clinical study at time of signing informed consent.
* Showering, bathing, or swimming within the 72 hour period prior to sampling for baseline screening, the test day, or throughout the test period.
* Pregnancy, plans to become pregnant or impregnate a sexual partner within the pre-test and test periods of the study, or nursing a child. All female subjects will be required to complete a urine pregnancy test on the day of test material application, prior to treatment. Both gender of subjects must be willing to use an acceptable method of contraception to prevent pregnancy for at least 14 days immediately preceding Treatment Day and throughout the duration of the study.
* Any medical condition or use of any medications that, in the opinion of the Principal Investigator or Consulting Physician, would preclude participation.
* Unwillingness to fulfill the performance requirements of the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes